Current status of stem cell transplantation for multiple myeloma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

Original languageEnglish (US)
Pages (from-to)229-240
Number of pages12
JournalCurrent Treatment Options in Oncology
Volume6
Issue number3
StatePublished - May 2005

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Transplants
Thalidomide
Survival
Standard of Care
Transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Current status of stem cell transplantation for multiple myeloma. / Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Hayman, Suzanne.

In: Current Treatment Options in Oncology, Vol. 6, No. 3, 05.2005, p. 229-240.

Research output: Contribution to journalArticle

@article{c99cae3bdd0b4ae38a020d066c353693,
title = "Current status of stem cell transplantation for multiple myeloma",
abstract = "Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90{\%}) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.",
author = "Morie Gertz and Martha Lacy and Angela Dispenzieri and Suzanne Hayman",
year = "2005",
month = "5",
language = "English (US)",
volume = "6",
pages = "229--240",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Current status of stem cell transplantation for multiple myeloma

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, Suzanne

PY - 2005/5

Y1 - 2005/5

N2 - Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

AB - Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

UR - http://www.scopus.com/inward/record.url?scp=21744458837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744458837&partnerID=8YFLogxK

M3 - Article

C2 - 15869734

AN - SCOPUS:21744458837

VL - 6

SP - 229

EP - 240

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 3

ER -